Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
Authors
Chen, RZinzani, PL
Lee, HJ
Armand, P
Johnson, NA
Brice, P
Radford, John A
Ribrag, V
Molin, D
Vassilakopoulos, TP
Tomita, A
von, Tresckow B
Shipp, MA
Lin, JX
Kim, E
Nahar, A
Balakumaran, A
Moskowitz, CH
Affiliation
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CAIssue Date
2019
Metadata
Show full item recordCitation
Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1144-53.Journal
BloodDOI
10.1182/blood.2019000324PubMed ID
31409671Additional Links
https://dx.doi.org/10.1182/blood.2019000324Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood.2019000324